Effect of anti-tuberculosis therapy on polymorphic drug metabolizing enzyme CYP2C9 using phenytoin as a probe drug

Indian Journal of Pharmacology

Volumn 44, Issue 4, 2012, Pages 485-488

  George, Melvin ^a   Shewade, Deepak Gopal ^a   Kumar, Saka Vinod ^a   Adithan, Chandrasekaran ^a  

^a JAWAHARLAL INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Anti tuberculosis therapy; CYP2C9; induction; inhibition; pharmacogenetics

Indexed keywords

4 HYDROXY PHENYL HYDANTOIN; CARBAMAZEPINE; CYTOCHROME P450 2C9; ETHAMBUTOL; HYDANTOIN; ISONIAZID; PHENYTOIN; PYRAZINAMIDE; RIFAMPICIN; UNCLASSIFIED DRUG;

ADULT; ALOPECIA; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; DIPLOPIA; DNA POLYMORPHISM; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG ERUPTION; DRUG INDUCED HEADACHE; DYSPEPSIA; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LUNG TUBERCULOSIS; METABOLITE; MYALGIA; NAUSEA; PHENOTYPE; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE DRUG DOSE; VOMITING;

ANTI-TUBERCULOSIS THERAPY; CYP2C9; INDUCTION; INHIBITION; PHARMACOGENETICS;

ADULT; ANTITUBERCULAR AGENTS; ARYL HYDROCARBON HYDROXYLASES; ENZYME INDUCTION; FEMALE; HUMANS; MALE; PHENYTOIN; POLYMORPHISM, GENETIC; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 84865750146     PISSN: 02537613     EISSN: 19983751     Source Type: Journal    
DOI: 10.4103/0253-7613.99314     Document Type: Article

References (24)

1. Global tuberculosis control 2010 fact sheet (2010) WHO web site. Available from: www.who.int. [Last accessed on 2011 June 9].
2. Rae JM, Johnson MD, Lippman ME, Flockhart DA. Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: Studies with cDNA and oligonucleotide expression arrays. J Pharmacol Exp Ther 2001;299:849-57.
3. Nishimura Y, Kurata N, Sakurai E, Yasuhara H. Inhibitory effect of anti-tuberculosis drugs on human cytochrome P450-mediated activities. J Pharmacol Sci 2004;96:293-300.
4. Kirchheiner J, Brockmoller J. Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin Pharmacol Ther 2005;77:1-16.
5. Miners JO, Birkett DJ. Cytochrome P4502C9: An enzyme of major importance in human drug metabolism. Br J Clin Pharmacol 1998;45:25-38.
6. Adithan C, Gerard N, Vasu S, Balakrishnan R, Shashindran CH, Krishnamoorthy R. Allele and genotype frequency of CYP2C9 in Tamil Nadu population. Eur J Clin Pharmacol 2003;59:707-9.
7. Sullivan-Klose TH, Ghanayem BI, Bell DA, Zhang ZY, Kaminsky LS, Shenfield GM, et al. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 1996;4:341-9.
8. Gerson B, Bell F, Chan S. Antiepileptic agents-primidone, phenobarbital, phenytoin, and carbamazepine by reversed-phase liquid chromatography. Clin Chem 1984;30:105-8.
9. Rosemary J, Surendiran A, Rajan S, Shashindran CH, Adithan C. Influence of the CYP2C9 AND CYP2C19 polymorphisms on phenytoin hydroxylation in healthy individuals from south India. Indian J Med Res 2006;123:665-70.
10. Hung CC, Lin CJ, Chen CC, Chang CJ, Liou HH. Dosage recommendation of phenytoin for patients with epilepsy with different CYP2C9/CYP2C19 polymorphisms. Ther Drug Monit 2004;26:534-40.
11. Acosta EP, Kendall MA, Gerber JG, Ston-Smith B, Koletar SL, Zolopa AR, et al. Effect of concomitantly administered rifampin on the pharmacokinetics and safety of atazanavir administered twice daily. Anti-microb Agents Chemother 2007;51:104-10.
12. Ament PW, Bertolino JG, Liszewski JL. Clinically significant drug interactions. Am Fam Physician 2011;61:1745-54.
13. Kay L, Kampmann JP, Svendsen TL, Vergman B, Hansen JE, Skovsted L, et al. Influence of rifampicin and isoniazid on the kinetics of phenytoin. Br J Clin Pharmacol 1985; 20:323-6.
14. Miller RR, Porter J, Greenblatt DJ. Clinical importance of the interaction of phenytoin and isoniazid: A report from the Boston collaborative drug surveillance program. Chest 1979;75:356-8.
15. Walubo A, Aboo A. Phenytoin toxicity due to concomitant anti-tuberculosis therapy. S Afr Med J 1995;85:1175-6.
16. Vormfelde SV, Brockmoller J, Bauer S, Herchenhein P, Kuon J, Meineke I, et al. Relative impact of genotype and enzyme induction on the metabolic capacity of CYP2C9 in healthy volunteers. Clin Pharmacol Ther 2009;86:54-61.
17. Zhou HH, Anthony LB, Wood AJ, Wilkinson GR. Induction of polymorphic 4'-hydroxylation of S-mephenytoin by rifampicin. Br J Clin Pharmacol 1990;30:471-5.
18. Tang C, Lin JH, Lu AY. Metabolism-based drug-drug interactions: What determines individual variability in cytochrome P450 induction? Drug Metab Dispos 2005;33:603-13.
19. Mills JB, Rose KA, Sadagopan N, Sahi J, De Morais SM. Induction of drug metabolism enzymes and MDR1 using a novel human hepatocyte cell line. J Pharmacol Exp Ther 2004;309:303-9.
20. Schuetz EG, Schinkel AH, Relling MV, Schuetz JD. P-glycoprotein: A major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humans. Proc Natl Acad Sci USA 1996;93:4001-5.
21. Tirona RG, Leake BF, Wolkoff AW, Kim RB. Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation. J Pharmacol Exp Ther 2003;304:223-8.
22. Zaher H, Zu Schwabedissen HE, Tirona RG, Cox ML, Obert LA, Agrawal N, et al. Targeted disruption of murine organic anion-transporting polypeptide 1b2 (Oatp1b2/Slco1b2) significantly alters disposition of prototypical drug substrates pravastatin and rifampin. Mol Pharmacol 2008;74:320-9.
23. Pascussi JM, Gerbal-Chaloin S, Pichard-Garcia L, Daujat M, Fabre JM, Maurel P, et al. Interleukin-6 negatively regulates the expression of pregnane X receptor and constitutively activated receptor in primary human hepatocytes. Biochem Biophys Res Commun 2000;274:707-13.
24. Zhang Y, Broser M, Rom WN. Activation of the interleukin 6 gene by mycobacterium tuberculosis or lipopolysaccharide is mediated by nuclear factors NF-IL6 and NF-kappa B. Proc Natl Acad Sci USA 1994;15:2225-9.